Nuvalent, Inc.

Equities

NUVL

US6707031075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
66.86 ^USD	+1.20%		+6.53%	-9.15%

Apr. 17	Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing	MT
Apr. 17	Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target	MT

Nuvalent, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 27, 2024 at 06:30 am EST

Nuvalent, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 126.22 million compared to USD 81.85 million a year ago. Basic loss per share from continuing operations was USD 2.17 compared to USD 1.65 a year ago.

Diluted loss per share from continuing operations was USD 2.17 compared to USD 1.65 a year ago.

Latest news about Nuvalent, Inc.

Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing	Apr. 17	MT
Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target	Apr. 17	MT
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing	Apr. 10	MT
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing	Apr. 01	MT
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69	Apr. 01	MT
Nuvalent Insider Sold Shares Worth $3,032,528, According to a Recent SEC Filing	Mar. 27	MT
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing	Mar. 25	MT
BMO Capital Raises Price Target on Nuvalent to $102 From $93, Maintains Outperform Rating	Feb. 28	MT
Nuvalent's Non-Small Cell Lung Cancer Drug Candidate Gets FDA Breakthrough Therapy Designation	Feb. 27	MT
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Nuvalent, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Baird Initiates Nuvalent With Outperform Rating, Price Target is $105	Feb. 23	MT
Nuvalent Starts Phase 2 Part of Clinical Trial of Potential Lung Cancer Treatment	Feb. 12	MT
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating	Feb. 12	MT
Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors	Feb. 12	CI
Nuvalent Outlines Three-Year Product Plan	Jan. 08	MT
Wedbush Raises Nuvalent's PT to $82 From $74 After Announced 3-Year Plan to Place At Least One Lead Asset on Market by 2026; Keeps Outperform Rating	Jan. 08	MT
Nuvalent Insider Sold Shares Worth $378,350, According to a Recent SEC Filing	Dec. 21	MT
Nuvalent Insider Sold Shares Worth $2,274,600, According to a Recent SEC Filing	Dec. 21	MT
Nuvalent Insider Sold Shares Worth $2,880,548, According to a Recent SEC Filing	Dec. 21	MT
Nuvalent Insider Sold Shares Worth $3,032,800, According to a Recent SEC Filing	Dec. 21	MT
Certain Class A Common Stock of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.	Dec. 15	CI
Certain Stock Options of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 16-DEC-2023.	Dec. 15	CI
Certain Class A Common Stock of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 1-DEC-2023.	Nov. 30	CI

Chart Nuvalent, Inc.

Duration

Period

More charts

Company Profile

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

66.86 USD

Average target price

101.1 USD

Spread / Average Target

+51.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NUVALENT, INC.	-9.15%	4.28B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research